Phase 3 Alzheimer Disease Clinical Trials
20 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 20 trials
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled241 locationsNCT06937229
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled157 locationsNCT07011732
Recruiting
Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Karuna Therapeutics406 enrolled278 locationsNCT06585787
Recruiting
Phase 3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled140 locationsNCT07011745
Recruiting
Phase 3
Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Alzheimer Disease, Early Onset
Assistance Publique - Hôpitaux de Paris240 enrolled1 locationNCT04661280
Recruiting
Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
Alzheimer Disease
Eli Lilly and Company3,400 enrolled3 locationsNCT07142954
Recruiting
Phase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
Alzheimer Disease
ScandiBio Therapeutics AB845 enrolled8 locationsNCT07062198
Recruiting
Phase 3
Nabilone for Agitation Blinded Intervention Trial
Alzheimer DiseaseAgitation
Sunnybrook Health Sciences Centre112 enrolled6 locationsNCT04516057
Recruiting
Phase 3
Biomarker Exploration in Aging, Cognition and Neurodegeneration
Cognitive ImpairmentCognitive DeclineAlzheimer Disease
University of California, Irvine300 enrolled1 locationNCT03860857
Recruiting
Phase 3
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
EpilepsyAlzheimer DiseaseSeizures+7 more
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau120 enrolled5 locationsNCT07234695
Recruiting
Phase 3
[18F]PI-2620 Phase 3 Histopathological Study
Alzheimer Disease
Life Molecular Imaging Ltd200 enrolled25 locationsNCT05641688
Recruiting
Phase 3
Clinical Analgesic Management in Dementia
Alzheimer Disease
Xuanwu Hospital, Beijing10 enrolled1 locationNCT07323914
Recruiting
Phase 3
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
Alzheimer DiseaseFrontotemporal Lobar DegenerationCognitively Normal
University of Pennsylvania72 enrolled1 locationNCT05456503
Recruiting
Phase 3
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
Alzheimer DiseaseNeurofibrillary Tangle
Sinotau Pharmaceutical Group354 enrolled1 locationNCT07115238
Recruiting
Phase 3
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Alzheimer DiseaseChronic Traumatic Encephalopathy
CereMark Pharma, LLC230 enrolled1 locationNCT06254469
Recruiting
Phase 3
Effect of CAFfeine on Cognition in Alzheimer's Disease
Alzheimer Disease
University Hospital, Lille248 enrolled17 locationsNCT04570085
Recruiting
Phase 2Phase 3
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Alzheimer DiseaseParkinson DiseaseDementia With Lewy Bodies+1 more
prof. dr. Koen Van Laere113 enrolled2 locationsNCT06120049
Recruiting
Phase 3
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
Alzheimer Disease
I.R.C.C.S. Fondazione Santa Lucia348 enrolled1 locationNCT06702124
Recruiting
Phase 2Phase 3
GnRH Therapy on Cognition in Down Syndrome
Cognitive DeclineAlzheimer Disease, Early OnsetDown Syndrome+1 more
Nelly Pitteloud56 enrolled1 locationNCT04390646